276 related articles for article (PubMed ID: 27913547)
1. New treatment approaches to von Willebrand disease.
Lavin M; O'Donnell JS
Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):683-689. PubMed ID: 27913547
[TBL] [Abstract][Full Text] [Related]
2. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.
Michiels JJ; van Vliet HH; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van der Velden A; Budde U
Clin Appl Thromb Hemost; 2007 Jan; 13(1):14-34. PubMed ID: 17164493
[TBL] [Abstract][Full Text] [Related]
3. Von Willebrand factor (Vonvendi®): the first recombinant product licensed for the treatment of von Willebrand disease.
Franchini M; Mannucci PM
Expert Rev Hematol; 2016 Sep; 9(9):825-30. PubMed ID: 27427955
[TBL] [Abstract][Full Text] [Related]
4. Desmopressin (DDAVP) use in patients with von Willebrand disease: A single-centre retrospective review of test response and clinical outcomes.
Chandrakumaran P; Hews-Girard J; Poon MC
Haemophilia; 2023 Jul; 29(4):1095-1103. PubMed ID: 37257847
[TBL] [Abstract][Full Text] [Related]
5. Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio.
Gadisseur A; Berneman Z; Schroyens W; Michiels JJ
Acta Haematol; 2009; 121(2-3):128-38. PubMed ID: 19506359
[TBL] [Abstract][Full Text] [Related]
6. A personalized approach to the management of VWD.
Phua CW; Berntorp E
Transfus Apher Sci; 2019 Oct; 58(5):590-595. PubMed ID: 31466808
[TBL] [Abstract][Full Text] [Related]
7. Guidelines for the evaluation of intravenous desmopressin and von Willebrand factor/factor VIII concentrate in the treatment and prophylaxis of bleedings in von Willebrand disease types 1, 2, and 3.
Michiels JJ; Gadisseur A; van der Planken M; Schroyens W; van de Velden A; Berneman Z
Semin Thromb Hemost; 2006 Sep; 32(6):636-45. PubMed ID: 16977574
[TBL] [Abstract][Full Text] [Related]
8. Von Willebrand Disease and Pregnancy: A Review of Evidence and Expert Opinion.
Reynen E; James P
Semin Thromb Hemost; 2016 Oct; 42(7):717-723. PubMed ID: 27648611
[TBL] [Abstract][Full Text] [Related]
9. The Effect of Age on von Willebrand Factor and Bleeding Symptoms in von Willebrand Disease.
Seaman CD; Ragni MV
Thromb Haemost; 2020 Aug; 120(8):1159-1165. PubMed ID: 32629500
[TBL] [Abstract][Full Text] [Related]
10. Prophylaxis in von Willebrand Disease: Coming of Age?
Saccullo G; Makris M
Semin Thromb Hemost; 2016 Jul; 42(5):498-506. PubMed ID: 27253087
[TBL] [Abstract][Full Text] [Related]
11. Von Willebrand factor/factor VIII concentrates in the treatment of von Willebrand disease.
Batlle J; López-Fernández MF; Fraga EL; Trillo AR; Pérez-Rodríguez MA
Blood Coagul Fibrinolysis; 2009 Mar; 20(2):89-100. PubMed ID: 19786936
[TBL] [Abstract][Full Text] [Related]
12. Highly purified VWF/FVIII concentrates in the treatment and prophylaxis of von Willebrand disease: the PRO. WILL Study.
Federici AB
Haemophilia; 2007 Dec; 13 Suppl 5():15-24. PubMed ID: 18078393
[TBL] [Abstract][Full Text] [Related]
13. Bleeding tendency and efficacy of anti-haemorrhagic treatments in patients with type 1 von Willebrand disease and increased von Willebrand factor clearance.
Castaman G; Tosetto A; Federici AB; Rodeghiero F
Thromb Haemost; 2011 Apr; 105(4):647-54. PubMed ID: 21264446
[TBL] [Abstract][Full Text] [Related]
14. The use of desmopressin in von Willebrand disease: the experience of the first 30 years (1977-2007).
Federici AB
Haemophilia; 2008 Jan; 14 Suppl 1():5-14. PubMed ID: 18173689
[TBL] [Abstract][Full Text] [Related]
15. Survival of von Willebrand factor released following DDAVP in a type 1 von Willebrand disease cohort: influence of glycosylation, proteolysis and gene mutations.
Millar CM; Riddell AF; Brown SA; Starke R; Mackie I; Bowen DJ; Jenkins PV; van Mourik JA
Thromb Haemost; 2008 May; 99(5):916-24. PubMed ID: 18449422
[TBL] [Abstract][Full Text] [Related]
16. Monitoring Therapy during Treatment of von Willebrand Disease.
Favaloro EJ; Pasalic L; Curnow J
Semin Thromb Hemost; 2017 Apr; 43(3):338-354. PubMed ID: 27472426
[TBL] [Abstract][Full Text] [Related]
17. Haemostatic management of intraoral bleeding in patients with von Willebrand disease.
Morimoto Y; Yoshioka A; Sugimoto M; Imai Y; Kirita T
Oral Dis; 2005 Jul; 11(4):243-8. PubMed ID: 15984956
[TBL] [Abstract][Full Text] [Related]
18. Epidemiology, diagnosis, and management of von Willebrand disease in India.
Ghosh K; Shetty S
Semin Thromb Hemost; 2011 Jul; 37(5):595-601. PubMed ID: 22102205
[TBL] [Abstract][Full Text] [Related]
19. Diagnosis and management of von Willebrand disease in Australia.
Favaloro EJ; Bonar R; Favaloro J; Koutts J
Semin Thromb Hemost; 2011 Jul; 37(5):542-54. PubMed ID: 22102198
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of a rapid von Willebrand factor activity latex immuno assay for monitoring of patients with von Willebrand disease (VWD) receiving DDAVP or VWF replacement therapy.
Vinayagam S; Simons LR; Chowdary P; Thurlow P; Brooks SV; Riddell AF
Haemophilia; 2014 Jul; 20(4):e304-10. PubMed ID: 24758424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
